NL0.F GRAIL, Inc.
- Market cap
- EUR 5.03B
- P/E
- -
- P/B
- 2.26x
- ROE
- -16.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NL0.F undervalued?
Graham numberThe Graham number of GRAIL, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GRAIL, Inc. fundamental analysis
No fundamental analysis for GRAIL, Inc. yet.
GRAIL, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GRAIL, Inc.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing,…
Full company profileGRAIL, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GRAIL, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 55.6M | 93.1M | 126M | 147M | 164M |
| Gross Profit | -116M | -95.6M | -78.0M | -62.6M | -60.0M |
| Operating Income | -742M | -797M | -768M | -534M | -572M |
| EBITDA | -588M | -638M | -610M | -378M | -417M |
| Net Income | -5.40B | -1.47B | -2.03B | -408M | -409M |
| EPS | -174 | -47 | -60 | -10 | -9.15 |
| Balance Sheet | |||||
| Total Assets | 4.94B | 3.91B | 2.98B | 2.92B | 2.73B |
| Total Liabilities | 292M | 268M | 480M | 344M | 277M |
| Shareholders' Equity | 0.00 | 0.00 | 2.50B | 2.58B | 2.45B |
| Cash & Short-term Investments | 242M | 97.3M | 214M | 250M | 29.0M |
| Cash Flow | |||||
| Operating Cash Flow | -561M | -596M | -577M | -299M | -323M |
| Capital Expenditure | 22.9M | 12.9M | 5.21M | 909K | 7.55M |
| Free Cash Flow | -584M | -609M | -582M | -300M | -331M |
| Ratios | |||||
| ROE | - | - | -81.0% | -15.8% | -16.7% |
| ROA | -109.3% | -37.4% | -67.9% | -14.0% | -15.0% |
| Net Profit Margin | -9,719.3% | -1,574.2% | -1,613.9% | -277.5% | -249.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
GRAIL, Inc. dividends
GRAIL, Inc. has not paid dividends in the last 4 fiscal years.
Who owns GRAIL, Inc.
- Insiders 4.76%
- Institutions 86.38%
- Public & others 8.86%
- Shares outstanding 45.0M
- Free float 34.6M
GRAIL, Inc. company profile
- Company name
- GRAIL, Inc.
- Ticker
- NL0.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Employees
- 910
- Fiscal year end
- December
- Address
- 250 S. Mathilda Avenue, Sunnyvale, CA, United States, 94086
- Phone
- (833) 694-2553
- Website
- grail.com
About GRAIL, Inc.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Sunnyvale, California.
GRAIL, Inc. management
10- Dr. Joshua J. Ofman M.D., M.S.H.SCEO & Director · born 1965
- Mr. Aaron FreidinCFO & Head of Corporate Development · born 1979
- Mr. Robert P. RagusaAdvisor · born 1960
- Mr. Paul CiccolellaSenior Vice President of Global Development & Operations
- Dr. Satnam Alag Ph.D.Chief Technology Officer
- Sir Harpal S. Kumar M.A., M.B.A., MEngChief Scientific Officer and President of Global Clinical & Medical Affairs
- Mr. Abram Barth J.D., M.P.H.Chief Legal Officer & Corporate Secretary
- Ms. Trish RowlandSenior Vice President of Corporate Communications
- Ms. Alison HighlanderChief People Officer
- Mr. Andrew John PartridgeChief Growth Officer · born 1969